Interesting Open Access Hidradenitis Suppurativa (HS) Reads – January 2025
Continuing from a busy December 2024 left off, PubMed recorded 101 #HidradenitisSuppurativa (HS)-related publications in January 2025. Of these, approx. 37% (37/101) were #openaccess.
1: Hidradenitis Suppurativa
One of the world’s most widely read medical journals, The Lancet, published this seminar on HS by an international team of authors (from the Americas and Europe). In addition to compiling a comprehensive, informative, and timely review on HS, the authors propose a pioneering framework for HS treatment.
Link: https://linkinghub.elsevier.com/retrieve/pii/S0140673624024759
Citation: Sabat R, Alavi A, Wolk K, Wortsman X, McGrath B, Garg A, Szepietowski JC. Hidradenitis suppurativa. Lancet. 2025 Feb 1;405(10476):420-438. doi: 10.1016/S0140-6736(24)02475-9. Epub 2025 Jan 22. PMID: 39862870.
2. Hidradenitis Suppurativa Treatment During Pregnancy and Lactation: Navigating Challenges
HS mainly affects young adults, particularly females, and often begins during the time when people have children. However, due to limited evidence and safety concerns, suitable treatment options are limited. This timely and useful systematic literature review highlights the need for a thorough investigation into the safety, efficacy, and suitability of management strategies during pregnancy and lactation.
Link: https://onlinelibrary.wiley.com/doi/10.1111/ijd.17672
Citation: Özbek L, Güldan M, Alpsoy E, Vural S. Hidradenitis Suppurativa Treatment During Pregnancy and Lactation: Navigating Challenges. Int J Dermatol. 2025 Jan 31. doi: 10.1111/ijd.17672. Epub ahead of print. PMID: 39887706.
3. Comparative Analyses of Hidradenitis Suppurativa Surgical Methods: A Systematic Review and Meta-Analysis
This systematic review and meta-analysis examined the literature for studies related to HS and surgery and compared procedures and wound healing techniques. The review included two randomized control trials (RCTs), two prospective, and 28 retrospective non-randomized studies of 52 interventions, involving 8240 procedures performed on 6922 patients, with a mean post-surgical follow-up of 22 months. The meta-analysis included only those studies with data available to calculate effect sizes.
Link: https://www.jaad.org/article/S0190-9622(25)00137-9/pdf
Citation: Li K, Peri K, Piguet V, Xu L, Chaudhry A, Lansang RP, Bouadi N, Asgarpour J, Goldberg S, Croitoru DO. Comparative Analyses of Hidradenitis Suppurativa Surgical Methods: A Systematic Review and Meta-Analysis. J Am Acad Dermatol. 2025 Jan 24:S0190-9622(25)00137-9. doi: 10.1016/j.jaad.2025.01.057. Epub ahead of print. PMID: 39864745.
4. Minimally Invasive Management of Hidradenitis Suppurativa Using a 1470 nm Diode Laser: a Step-by-Step Description of our Technique
Due to the recurrent nature of HS and often need for repeat procedures, management ought to focus on tissue preservation. The authors of this study describe using a minimally invasive diode laser for the management of different stages of HS and demonstrate a possible role for this technique in the management of HS.
Link: https://bmcsurg.biomedcentral.com/articles/10.1186/s12893-024-02686-8
Citation: Brown NKD, Kumassah PK, Brown GD, Brookmann S, Ambe PC, Agbedinu K. Minimally invasive management of hidradenitis suppurativa using a 1470 nm diode laser: a step-by-step description of our technique. BMC Surg. 2025 Jan 23;25(1):36. doi: 10.1186/s12893-024-02686-8. PMID: 39849423.
5. Pediatric Hidradenitis Suppurativa: An Overview
The authors of this overview focus on paediatric HS, a challenging clinical entity to diagnose and manage. The authors discuss the epidemiology, pathogenesis, multiple comorbidities, and many management challenges associated with paediatric HS.
Link: https://www.skintherapyletter.com/hidradenitis-suppurativa/pediatric-overview/
Citation: Roesler J, Gregory A, Rehmus W. Pediatric Hidradenitis Suppurativa: An Overview. Skin Therapy Lett. 2025 Jan;30(1):1-4. PMID: 39814056.
6. Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging Association
As widely reported in the literature, many other conditions are associated with HS (known as ‘comorbidities’). The authors of this retrospective, single-centre observational study (involving 60 patients with HS) explored associations between hypergammaglobulinemia and HS based on sex, age, disease severity (IHS4 score), and adalimumab treatment. The team report hypergammaglobulinemia in 68% of patients, with the highest prevalence (80%) in the 15–29 age group. In addition, hypergammaglobulinemia was also found to be associated with increased disease severity, particularly in younger patients with HS. Further researchis required to determine whether hypergammaglobulinemia is merely a marker or contributes to HS pathogenesis.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC11724707/pdf/ccid-18-1.pdf
Citation: Martora F, Battista T, Giordano A, Potestio L, Megna M. Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging Association. Clin Cosmet Investig Dermatol. 2025 Jan 7;18:1-5. doi: 10.2147/CCID.S503199. PMID: 39802669.
7. Management of Hidradenitis Suppurativa in the Inpatient Setting: a Clinical Guide
Many patients with HS will, at some point(s), seek care in emergency departments and may require hospitalization. However, there are a lack of clear admission criteria and management guidelines. The authors of this report conducted a clinical review aimed at hospitalists and consulting dermatologists considering hospital admission for patients with HS experiencing severe HS flares. By providing clear and comprehensive guidance on its management in the inpatient setting, the authors aim to improve care for HS.
Link: https://link.springer.com/article/10.1007/s00403-024-03622-9
Citation: Maskan Bermudez N, Elman SA, Kirsner RS, Lev-Tov H. Management of hidradenitis suppurativa in the inpatient setting: a clinical guide. Arch Dermatol Res. 2025 Jan 8;317(1):202. doi: 10.1007/s00403-024-03622-9. PMID: 39777571.
8. Exploring Health Literacy Among Adults with Hidradenitis Suppurativa
Health literacy is defined by the World Health Organization (WHO) as “being able to access, understand, appraise and use information and services in ways that promote and maintain good health and well-being”. Sufficient health literacy empowers people to understand their disease, manage it effectively, and make informed decisions about their health, which is beneficial to all.
This study from the Netherlands explored the prevalence of limited health literacy levels and associated factors in adult patients with HS. The authors report that limited health literacy among patients with HS was associated with higher body mass index (BMI), lower education level, lower socioeconomic status, and more severe disease. Interventions to increase health literacy could enhance care quality and improve outcomes for patients with HS.
Link: https://karger.com/drm/article-pdf/doi/10.1159/000543286/4319527/000543286.pdf
Citation: Koerts NDK, Horváth B. Exploring Health Literacy among Adults with Hidradenitis Suppurativa. Dermatology. 2025 Jan 3:1-10. doi: 10.1159/000543286. Epub ahead of print. PMID: 39756388.
9. Microbial Colonization and Antibiotic Resistance Profiles in Chronic Wounds: A Comparative Study of Hidradenitis Suppurativa and Venous Ulcers
This study investigated the microbial populations and antibiotic resistance profiles in chronic wounds in patients with HS (n-24) and in patients with venous ulcers (n=88) and compared the prevalence of pathogens and their antimicrobial resistance profiles found in each. Staphylococcus aureus was the most common pathogen found in each group, with a notable prevalence of methicillin-resistant S. aureus (MRSA). Other common pathogens found in wounds in patients HS only were beta-hemolytic Streptococcus and Corynebacterium amycolatum. Antibiotic resistance was moderate, notably in S. aureus. Distinctive microbial profiles and antibiotic resistance patterns were noted in HS and venous ulcer chronic wounds, while the predominance of S. aureus in both groups underscores the need for targeted therapies.
Link: https://www.mdpi.com/2079-6382/14/1/53
Citation: Sandru F, Poenaru E, Stoleru S, Radu AM, Roman AM, Ionescu C, Zugravu A, Nader JM, Băicoianu-Nițescu LC. Microbial Colonization and Antibiotic Resistance Profiles in Chronic Wounds: A Comparative Study of Hidradenitis Suppurativa and Venous Ulcers. Antibiotics (Basel). 2025 Jan 9;14(1):53. doi: 10.3390/antibiotics14010053. PMID: 39858339.
10. Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa
The past couple of years have witnessed the approval of two new treatment options for moderate to severe HS in Europe, the USA, and beyond, with both treatment options targeting IL-17. Ongoing clinical trials are evaluating the efficacy and safety of IL-17 inhibitors. This review offers a comprehensive overview of current knowledge and scientific advances in HS, focusing on the IL-17 pathway’s role and its inhibition as a treatment strategy, alongside examining the most recent and significant clinical studies on various IL-17 inhibitors in the treatment of HS.
Link: https://link.springer.com/article/10.1007/s40259-024-00687-w
Citation: Pinto Salgueiro G, Yilmaz O, Nogueira M, Torres T. Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa. BioDrugs. 2025 Jan;39(1):53-74. doi: 10.1007/s40259-024-00687-w. Epub 2024 Nov 28. PMID: 39604776.
